SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-056219
Filing Date
2021-11-10
Accepted
2021-11-10 16:25:46
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tnya-8k_20211110.htm   iXBRL 8-K 36739
2 EX-99.1 tnya-ex991_6.htm EX-99.1 294285
3 GRAPHIC ged02ugwocao000001.jpg GRAPHIC 6169
  Complete submission text file 0001564590-21-056219.txt   486810

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tnya-20211110.xsd EX-101.SCH 5725
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tnya-20211110_lab.xml EX-101.LAB 20073
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tnya-20211110_pre.xml EX-101.PRE 11964
7 EXTRACTED XBRL INSTANCE DOCUMENT tnya-8k_20211110_htm.xml XML 3699
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 211397060
SIC: 2836 Biological Products, (No Diagnostic Substances)